Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

Nature·2026
Same author

Profiling Dietary Patterns for Metabolic Syndrome: A Study Integrating Reduced Rank Regression and Food Network Visualization.

Journal of epidemiology·2026
Same author

Time trend of sugar-sweetened beverages intake from 2002 to 2022 among adults in Beijing, China.

Preventive medicine reports·2026
Same author

Adherence to Life's Essential 8 is associated with lower risk of hyperuricemia among adults in Beijing, China.

Frontiers in nutrition·2026
Same author

Trends in diet structural composition and quality among adults in Beijing, China (2010-2022).

Frontiers in nutrition·2025
Same author

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood·2025

Related Experiment Video

Updated: May 17, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Biomarkers for systemic lupus erythematosus.

Ronald Herbst1, Zheng Liu, Bahija Jallal

  • 1MedImmune, LLC, Gaithersburg, Maryland 20878, USA. herbstR@medimmune.com

International Journal of Rheumatic Diseases
|October 23, 2012
PubMed
Summary

Biomarkers are crucial for developing new systemic lupus erythematosus (SLE) treatments. This review highlights promising biomarkers like the type I interferon (IFN) gene signature and anti-double stranded DNA for improved SLE drug development and patient care.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Related Experiment Videos

Last Updated: May 17, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease with limited treatment options.
  • The development of new SLE therapies is hindered by disease heterogeneity and a lack of validated biomarkers for treatment decisions.
  • Belimumab is the only FDA-approved drug for SLE in the last 50 years, underscoring a significant unmet medical need.

Purpose of the Study:

  • To review promising biomarkers for improving drug development and clinical decision-making in SLE.
  • To highlight specific biomarkers with potential impact on SLE treatment strategies.

Main Methods:

  • Literature review of current research on biomarkers in SLE drug development.
  • Identification and discussion of key biomarkers, including type I interferon (IFN) gene signature, anti-double stranded DNA (anti-dsDNA), complement and neutrophil signatures, TWEAK, and MCP-1.

Main Results:

  • Type I IFN gene signature shows potential as a pharmacodynamic and predictive marker for anti-IFN therapy.
  • Anti-dsDNA may serve as a disease and predictive marker for SLE flares.
  • Complement and neutrophil signatures are identified as disease markers, while TWEAK and MCP-1 show potential for predicting renal flares.

Conclusions:

  • Validated biomarkers are essential for advancing SLE drug development and personalizing patient treatment.
  • Further high-powered prospective studies are required to confirm the utility of the discussed biomarkers.
  • Emerging technologies will likely yield more effective biomarkers for managing SLE and developing novel therapeutics.